{
  "stream_name": "Palatin Scientific Literature Monitor",
  "purpose": "Monitor newly published scientific and medical literature that highlights opportunities and risks relevant to Palatin's ongoing research programs in melanocortin pathway therapeutics. This stream informs research direction, study design, and competitive landscape awareness across obesity, ocular disease, gastrointestinal/renal disease, and sexual dysfunction indications.",
  "channels": [
    {
      "name": "Melanocortin Pathway Research",
      "focus": "Track fundamental scientific research on melanocortin receptors (MCR1, MCR4, MCR5) and pathway mechanisms relevant to therapeutic development",
      "type": "scientific",
      "keywords": [
        "melanocortin",
        "MCR1",
        "MCR4",
        "MCR5",
        "alpha-MSH",
        "melanocyte stimulating hormone",
        "melanocortin receptor",
        "melanocortin pathway",
        "MC1R agonist",
        "MC4R agonist"
      ]
    },
    {
      "name": "Obesity & Metabolic Disease",
      "focus": "Monitor scientific literature on melanocortin pathways in obesity, binge eating, and metabolic disease, including competitive developments",
      "type": "scientific",
      "keywords": [
        "obesity",
        "binge eating",
        "metabolic disease",
        "bremelanotide obesity",
        "GLP-1 adjuvant",
        "MCR4 agonist obesity",
        "PL7737",
        "MC4R agonist peptide",
        "weight loss melanocortin"
      ]
    },
    {
      "name": "Ocular Disease Research",
      "focus": "Track research on melanocortin pathways in ocular indications including dry eye disease, glaucoma, and retinal diseases",
      "type": "scientific",
      "keywords": [
        "dry eye disease",
        "DED",
        "glaucoma",
        "retinal disease",
        "ocular inflammation",
        "PL9643",
        "PL9588",
        "PL9654",
        "melanocortin ocular",
        "MCR agonist eye"
      ]
    },
    {
      "name": "Gastroenterology & Renal Disease",
      "focus": "Monitor scientific literature on melanocortin pathways in gastrointestinal and renal indications",
      "type": "scientific",
      "keywords": [
        "ulcerative colitis",
        "UC",
        "diabetic nephropathy",
        "PL8177",
        "MC1R agonist",
        "melanocortin gastrointestinal",
        "melanocortin renal",
        "inflammatory bowel disease melanocortin"
      ]
    },
    {
      "name": "Sexual Dysfunction (Secondary)",
      "focus": "Monitor developments in melanocortin pathways for sexual dysfunction, particularly as they relate to Vyleesi (bremelanotide) milestone payments and retained rights for other indications",
      "type": "scientific",
      "keywords": [
        "female sexual dysfunction",
        "HSDD",
        "hypoactive sexual desire disorder",
        "bremelanotide",
        "Vyleesi",
        "male erectile dysfunction",
        "melanocortin sexual function"
      ]
    }
  ],
  "report_frequency": "weekly",
  "workflow_config": {
    "sources": [
      {
        "source_name": "PubMed",
        "source_type": "academic_database",
        "search_strategy": "keyword_based",
        "notes": "National Library of Medicine's PubMed Database"
      },
      {
        "source_name": "Google Scholar",
        "source_type": "academic_search_engine",
        "search_strategy": "keyword_based"
      }
    ],
    "search_frequency": "daily",
    "article_limit_per_week": 10
  },
  "scoring_config": {
    "relevance_scoring": {
      "enabled": true,
      "scale": "1-10",
      "weight": 0.6,
      "criteria": "Relevance to Palatin's ongoing research programs and business goals"
    },
    "evidence_hierarchy_scoring": {
      "enabled": true,
      "scale": "1-10",
      "weight": 0.4,
      "criteria": "Scientific rigor based on evidence hierarchy (systematic reviews, RCTs, observational studies, etc.)"
    },
    "integrated_score_threshold": 7.0,
    "notes": "Integrated score = (Relevance * 0.6) + (Evidence Hierarchy * 0.4). Articles with integrated score >= 7.0 are included in weekly alert."
  },
  "metadata": {
    "company": "Palatin Technologies",
    "industry": "Biopharmaceutical",
    "primary_focus": "Melanocortin pathway therapeutics",
    "therapeutic_areas": [
      "Obesity",
      "Ocular Disease",
      "Gastrointestinal Disease",
      "Renal Disease",
      "Sexual Dysfunction"
    ],
    "key_assets": [
      "Bremelanotide (obesity, ED)",
      "PL7737 (oral MC4R agonist, obesity)",
      "PL9643 (MCR agonist, dry eye)",
      "PL9588 (MCR agonist, glaucoma)",
      "PL9654 (MCR agonist, retinal disease)",
      "PL8177 (oral MC1R agonist, ulcerative colitis)"
    ],
    "competitive_context": "Monitor competitive developments in melanocortin pathway research, particularly GLP-1 combination therapies and novel MCR4 agonists",
    "business_objectives": [
      "Inform research direction and study design",
      "Identify opportunities and risks",
      "Stay current on competitive landscape",
      "Support strategic decision-making"
    ]
  }
}
